Cargando…
Pixantrone beyond monotherapy: a review
Outcomes for patients with non-Hodgkin’s lymphoma (NHL) that proves refractory to treatment remain poor. Treatment of such patients is individualized and can include enrolment in a clinical trial of novel agents or use of one of a wide array of drug regimens. Initial treatment with anthracyclines su...
Autores principales: | Barrenetxea Lekue, Cristina, Grasso Cicala, Silvina, Leppä, Sirpa, Stauffer Larsen, Thomas, Herráez Rodríguez , Susana, Alonso Caballero, Clara, Jørgensen, Judit M., Toldbod, Helle, Leal Martínez, Irene, D’Amore, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700039/ https://www.ncbi.nlm.nih.gov/pubmed/31312929 http://dx.doi.org/10.1007/s00277-019-03749-0 |
Ejemplares similares
-
Pixantrone Sensitizes Gram-Negative Pathogens to Rifampin
por: She, Pengfei, et al.
Publicado: (2022) -
Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma
por: Vajavaara, Heli, et al.
Publicado: (2021) -
Low Absolute Lymphocyte Counts in the Peripheral Blood Predict Inferior Survival and Improve the International Prognostic Index in Testicular Diffuse Large B-Cell Lymphoma
por: Vähämurto, Pauli, et al.
Publicado: (2020) -
Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma
por: Novakovic, Aleksander, et al.
Publicado: (2020) -
Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
por: Jezeršek Novaković, Barbara, et al.
Publicado: (2021)